Ibritumomab Tiuxetan (Systemic)
Brand Names : Zevalin, IDEC-2B8 (ibritumomab tiuxetan), IDEC-Y2B8 (yttrium-90–ibritumomab tiuxetan), IDEC-In2B8 (indium-111–ibritumomab tiuxetan), IDEC-129
Category- Monoclonal antibody
- antineoplastic (radioactive)
DescriptionIbritumomab Tiuxetan (ib-ri-TU-moe-mab) (tie-ux-EH-tan) is a
protein called a monoclonal antibody. It is used along with another monoclonal
antibody (rituximab) and two radioactive pharmaceuticals (In-111 and Y-90).
Ibritumomab tiuxetan is used to treat a type of cancer called non-Hodgkin's
lymphoma.
Ibritumomab Tiuxetan is to be administered only by or under the immediate
supervision of your doctor. It is available in the following dosage form:
Parenteral
-
Injection (U.S.)
Brand NamesSome commonly used brand names are:
In the U.S. -
Other commonly used names are:
-
IDEC-2B8 (ibritumomab tiuxetan)
-
IDEC-Y2B8 (yttrium-90-ibritumomab tiuxetan)
-
IDEC-In2B8 (indium-111-ibritumomab tiuxetan)
-
IDEC-129
† Not commercially available in Canada.
|